EAPA 115
Alternative Names: EAPA-115Latest Information Update: 28 Feb 2023
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea (PO)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 18 Jan 2020 EAPA 115 is available for licensing as of 18 Jan 2020. http://www.cjp.co.kr/eng/business/out_licensing.asp